Clinical Trials Directory

Trials / Terminated

TerminatedNCT00746720

Modulation of the Surgical Inflammatory Response by Etoricoxib

Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral Versus Central

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
23 (actual)
Sponsor
University of Erlangen-Nürnberg Medical School · Academic / Other
Sex
All
Age
55 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to test the hypothesis that orally administered etoricoxib (COX-2) modulates prostaglandin and cytokine synthesis in the central nervous system (CNS) and in the periphery in surgical patients and thus reduces pain and suffering.

Detailed description

This study will be a multiple centre, double-blind, placebo-controlled, randomized, parallel group study conducted in male and female adult patients undergoing elective primary single hip arthroplasty. In part 1 of the study 12 patients will be enrolled in the study and will be administrated 120 mg Etoricoxib or placebo orally on day one post surgery. The results from part 1 should help to adjust sampling time points (for blood, cerebrospinal fluid and hip drain fluid) if necessary. In part 2 of the study 40 patients will be enrolled and should receive 120 mg etoricoxib or placebo two hours before and 24 hours after surgery. Primary end points will be the inflammatory mediators on peripheral and central levels. After surgical manipulation we expect increased mediators on both sides. It will be investigated if the medication could reduce the mediators compared to placebo and if the effect is related to pharmacokinetic parameters.

Conditions

Interventions

TypeNameDescription
DRUGEtoricoxib 60 mgfilm coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
DRUGPlacebo for Etoricoxib 60 mgfilm coated tablet (orally), two tablets once daily, on day one post surgery
DRUGEtoricoxib 60 mgfilm coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
DRUGPlacebo for Etoricoxib 60 mgfilm coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery

Timeline

Start date
2006-05-01
Primary completion
2009-07-01
Completion
2010-12-01
First posted
2008-09-04
Last updated
2020-12-14

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00746720. Inclusion in this directory is not an endorsement.